Formulary management of 2 new agents: Lorcaserin and phentermine/topiramate for weight loss

Journal of Managed Care Pharmacy

Volumn 19, Issue 8, 2013, Pages 642-654

  Kelly, Elizabeth M ^a   Tungol, Alexandra A ^b   Wesolowicz, Laurie A ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Blue Cross Blue Shield of Michigan   (United States)

^c Blue Cross Blue Shield of Michigan Cardiovascular Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; AMINOREX; BENZPHETAMINE; CYTOCHROME P450 3A4; DESIPRAMINE; DEXFENFLURAMINE; DEXTROMETHORPHAN; DOSPAN; FENFLURAMINE; LORCASERIN; METHAMPHETAMINE; NON PRESCRIPTION DRUG; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENYLPROPANOLAMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TANDIL; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONSTIPATION; COUGHING; DEFECATION DISORDER; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULARY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECALL; DRUG SAFETY; DYSGEUSIA; ENDOCRINE DISEASE; FATIGUE; FECES INCONTINENCE; GASTROINTESTINAL DISEASE; GROWTH DISORDER; HEADACHE; HEART INFARCTION; HEART RATE; HEMATOLOGIC DISEASE; HUMAN; HYPOGLYCEMIA; INSOMNIA; LIPID DIET; MANAGED CARE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OBESITY; OILY STOOL; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRESCRIPTION; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TERATOGENICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; UROGENITAL TRACT DISEASE; VALVULAR HEART DISEASE; WEIGHT CHANGE; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BENZAZEPINES; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; OBESITY; PHENTERMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 84885415879     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.8.642     Document Type: Article

References (54)

1. World Health Organization. Obesity and overweight. March 2013. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed June 21, 2013.
2. National Center for Health Statistics. Health, United States, 2011: with special feature on socioeconomic status and health. Hyattsville, MD. 2012. Available at: http://www.cdc.gov/nchs/data/hus/hus11.pdf#069. Accessed June 21, 2013.
3. Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012;36()1):13-25. Available at: http://e-dmj.org/ DOIx.php?id=10.4093/dmj.2012.36.1.13. Accessed June 21, 2013.
4. National Heart, Lung, and Blood Institute. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication No. 00-4084. October 2000. Available at: http://www.nhlbi.nih. gov/guidelines/obesity/prctgd_c.pdf. Accessed June 21, 2013.
5. U.S. Food and Drug Administration. Drugs. Fen-Phen safety update information. July 17, 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm072820.htm. Accessed June 21, 2013.
6. Daily Med. Meridia (sibutramine hydrochloride) capsule. Abbott Laboratories. August 2010. Available at: http://dailymed.nlm. nih.gov/dailymed/lookup.cfm?setid=c0333e62-bb00-4722-27b6- dca6ab4d1eb1#nlm34071-1. Accessed June 21, 2013.
7. U.S. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. May 17, 2013. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm. Accessed June 21, 2013.
8. Begley, S. As America's waistline expands, costs soar. Reuters. April 30, 2012. Available at: http://www.reuters.com/article/2012/04/30/us-obesityidUSBRE83T0C820120430. Accessed June 21, 2013.
9. Centers for Disease Control and Prevention. CDC newsroom. Press briefing transcript. CDC weight of the nation press briefing. May 7, 2012. Available at: http://www.cdc.gov/media/releases/2012/t0507_weight_nation. html. Accessed June 21, 2013.
10. Centers for Disease Control and Prevention. Healthy weight - it's not a diet, it's a lifestyle! Balancing calories. October 31, 2011. Available at: http:// www.cdc.gov/healthyweight/calories/index.html. Accessed June 21, 2013.
11. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn R. Clinical management of metabolic syndrome: report of the American Heart Association/ National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol. 2004;24(2):e19-e24. Available at: http://atvb.ahajournals.org/content/ 24/2/e19.full.pdf+html. Accessed June 21, 2013.
12. Katzmarzyk PT, Lear SA. Physical activity for obese individuals: a systematic review of effects on chronic disease risk factors. Obes Rev. 2012;13(2):95-105.
13. National Institutes of Health. National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) executive summary. NIH Publication No. 01-3670. May 2001. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3xsum.pdf. Accessed June 21, 2013.
14. U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. AHRQ Publication No. 11-05159-EF-2. June 2012. Available at: http:// www.uspreventiveservicestaskforce.org/uspstf11/obeseadult/obesers.htm. Accessed June 21, 2013.
15. American Diabetes Association. Standards of medical care in diabetes- 2013. Diabetes Care. 2013;36(Suppl 1):S11-S66. Available at: http://care. diabetesjournals.org/content/36/Supplement_1/S11.full. Accessed June 21, 2013.
16. Hurren KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm. 2011;68(21):2029-37.
17. Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Devel Ther. 2010;5:1-7.
18. Rubino DM, Gadde KM. A review of topiramate and phentermine: a combined therapeutic approach for obesity. Clin Lipidol. 2012;7(1):13-25.
19. Qsymia eDossier. Qsymia (phentermine and topiramate extendedrelease) capsules. AMCP eDossier System. Vivus, Inc. October 2012.
20. Qsymia (phentermine and topiramate extended release). Vivus, Inc. Updated April 2013. Available at: http://www.vivus.com/docs/QsymiaPI.pdf. Accessed June 21, 2013.
21. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebocontrolled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-56. Available at: http://www.nejm.org/doi/full/10.1056/ NEJMoa0909809. Accessed June 21, 2013.
22. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-77. Available at: http://jcem. endojournals.org/content/96/10/3067.long. Accessed June 21, 2013.
23. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426-36.
24. U.S. Food and Drug Administration. Guidance for industry developing products for weight management. Draft guidance. February 2007. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071612.pdf. Accessed June 21, 2013.
25. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Summary review of lorcaserin. Application number 022529. August 7, 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_ docs/nda/2012/022529Orig1s000SumR.pdf. Accessed June 21, 2013.
26. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577-79. Available at: http://www.nejm.org/doi/ full/10.1056/NEJMp1211277. Accessed June 21, 2013.
27. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-52.
28. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/ topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-42. Available at: http://www. ncbi.nlm.nih.gov/pmc/articles/PMC3270297/. Accessed June 21, 2013.
29. Walker J. UPDATE: Vivus gets FDA approval to sell diet drug in stores. The Wall Street Journal. April 16, 2013. Available at: http://online.wsj.com/ article/BT-CO-20130416-713870.html?mod=googlenews_wsj. Accessed June 21, 2013.
30. Vivus, Inc. VIVUS submits REMS amendment to FDA for Qsymia (phentermine and topiramate extended-release) capsules CIV. News release. October 17, 2012. Available at: http://ir.vivus.com/releasedetail. cfm?ReleaseID=714128. Accessed June 21, 2013.
31. Gefvert A. Why the FDA's approval of lorcaserin is bad news for Orexigen Therapeutics. Seeking Alpha. June 28, 2012. Available at: http:// seekingalpha.com/article/688981-why-the-fda-s-approval-of-lorcaserin-isbad- news-for-orexigen-therapeutics. Accessed June 21, 2013.
32. Edney A. FDA considers faster approval process for obesity drugs. Bloomberg News. October 11, 2012. Available at: http://www.businessweek. com/news/2012-10-11/fda-considers-faster-approval-process-for-obesitydrugs. Accessed June 21, 2013.
33. Burton TM. FDA urged to speed approval of drugs. The Wall Street Journal. September 25, 2012. Available at: http://online.wsj.com/article/SB1 0000872396390444083304578018790623838634.html. Accessed June 21, 2013.
34. Armstrong D, Flinn R. Vivus's weight-loss pill covered by insurers 30% of the time. Bloomberg News. October 1, 2012. Available at: http://www. bloomberg.com/news/2012-10-01/vivus-s-weight-loss-pill-covered-by-insurers- 30-of-the-time.html?cmpid=yhoo. Accessed June 21, 2013.
35. Dey E, Siddiqui Z. Vivus's obesity pill to be covered by Express Scripts. Reuters. December 20, 2012. Available at: http://www.reuters.com/article/ 2012/12/20/us-vivus-obesitydrug-coverage-idUSBRE8BJ0KW20121220. Accessed July 3, 2013.
36. Aetna. Clinical policy bulletin: weight reduction medications and programs. Policy. November 20, 2012. Available at: http://www.aetna.com/cpb/ medical/data/1_99/0039.html. Accessed June 21, 2013.
37. Centers for Disease Control and Prevention. Adult obesity facts. August 13, 2012. Available at: http://www.cdc.gov/obesity/data/adult.html. Accessed June 21, 2013.
38. U.S. Food and Drug Administration. Medications target longterm weight control. July 17, 2012. Available at: http://www.fda.gov/ ForConsumers/ConsumerUpdates/ucm312380.htm. Accessed June 21, 2013.
39. Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42(6):563-70. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/0749-3797/ PIIS0749379712001468.pdf. Accessed June 21, 2013.
40. GlobalData. Anti-obesity-drug pipeline analysis and market forecasts to 2016. PRLOG Press Release Distribution. January 11, 2010. Available at: http://www.prlog.org/10483087-antiobesity-drug-pipeline-analysis-andmarket- forecasts-to-2016.html. Accessed June 21, 2013.
41. Medi-Span. Price Rx. Walker Kluwers Health. Available at: http://www. medispan.com/drug-pricing-analysis-pricerx.aspx. Accessed June 21, 2013.
42. Stempel J. U.S. court voids drug rep's conviction, cites free speech. Reuters. December 3, 2012. Available at: http://www.reuters.com/article/ 2012/12/04/us-offlabel-conviction-idUSBRE8B21DC20121204. Accessed June 21, 2013.
43. Belviq (lorcaserin). Arena Pharmaceuticals GmbH. Revised August 2012. Available at: http://us.eisai.com/package_inserts/BelviqPI.pdf. Accessed June 21, 2013.
44. Didrex (benzphetamine hydrochloride tablet). Pharmacia and Upjohn Company. February 5, 2010. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2010/012427s026lbl.pdf. Accessed June 21, 2013.
45. Tenuate (diethylpropion hydrochloride immediate release tablet). Aventis Pharmaceuticals Company. November 2003. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2004/11722s029,12546s032lbl. pdf. Accessed June 21, 2013.
46. Desoxyn (methamphetamine hydrochloride tablets). Ovation Pharmaceuticals, Inc. March 2007. Available at: http://www.accessdata.fda. gov/drugsatfda_docs/label/2007/005378s026lbl.pdf. Accessed June 21, 2013.
47. Xenical (orlistat). Genentech USA, Inc. January 2012. Available at: http:// www.gene.com/download/pdf/xenical_prescribing.pdf. Accessed June 21, 2013.
48. Alli (orlistat). GlaxoSmithKline. February 2007. Available at: http:// www.accessdata.fda.gov/drugsatfda_docs/label/2007/021887lbl.pdf. Accessed June 21, 2013.
49. Phendimetrazine tartrate (extended release capsules). Epic Pharma, LLC. October 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/018074s034lbl.pdf. Accessed June 21, 2013.
50. Adipex-P (phentermine). Teva Pharmaceuticals USA. January 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/085128s065lbl.pdf. Accessed June 21, 2013.
51. Fishman A. Aminorex to fen/phen: an epidemic foretold. Circulation. 1999;99(1):156-61. Available at: http://circ.ahajournals.org/content/ 99/1/156.full. Accessed June 21, 2013.
52. Rodgers RJ, Tschöp MH, Wilding JP. Anti-obesity drugs: past present and future. Dis Model Mech. 2012;5(5):621-26. Available at: http://www.ncbi. nlm.nih.gov/pmc/articles/PMC3424459/?report. Accessed June 21, 2013.
53. U.S. Food and Drug Administration. Drugs. FDA announces withdrawal fenfluramine and dexfenfluramine (fen-phen). Updated August 21, 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. Accessed June 21, 2013.
54. U.S. Food and Drug Administration. Drugs. Science background- safety of phenylpropanolamine. Updated May 12, 2009. Available at: http:// www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm150771.htm. Accessed June 21, 2013.